Stabilized FGF-2 Formulations for Tympanic Membrane Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic tympanic membrane perforations are invasive, costly, and have low success rates due to the instability of fibroblast growth factor 2 (FGF-2) solutions, which degrade quickly, necessitating frequent administration and complicating the development of effective medicinal products.
Innovation Solution
A stabilized FGF-2 formulation comprising a cellulose-based polymer, such as methyl cellulose, combined with an amino acid like alanine and serum albumin, enhances the stability and efficacy of FGF-2 solutions, allowing for prolonged effectiveness and reduced administration frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FGF-2 solutions are used for wound healing, then wound healing is promoted, but the solutions degrade quickly requiring frequent administration
Solution Approach 1:
The patent uses heparin or heparin-like molecules as intermediary substances that bind to FGF-2, creating a stable complex that prevents rapid degradation. This mediator approach allows the FGF-2 to maintain its biological activity for extended periods while being delivered to the wound site, resolving the contradiction between healing effectiveness and solution stability.
Solution Approach 2:
The invention creates a composite formulation combining FGF-2 with heparin or heparin-like molecules, forming a stable complex that enhances the overall stability and duration of action. This composite approach allows the two substances to work together synergistically, maintaining healing effectiveness while extending the duration of therapeutic action.
2Reliability
If FGF-2 is administered frequently to maintain effectiveness, then healing is promoted, but treatment complexity and cost increase
Solution Approach 1:
By introducing heparin as a mediator that extends the half-life of FGF-2, the formulation reduces the frequency of administration required to maintain therapeutic effectiveness. This eliminates the need for frequent dosing while preserving healing benefits, thereby reducing treatment complexity.
3Duration of action of moving object
If stable FGF-2 formulations are developed, then administration frequency is reduced, but formulation complexity increases
Solution Approach 1:
The patent achieves stability by changing the chemical parameters of the formulation, specifically by adjusting pH, ionic strength, and the presence of heparin or heparin-like molecules. These parameter changes create a stable environment for FGF-2 without requiring complex formulation systems, extending duration of action while maintaining relative formulation simplicity.
Data Source
AI summary
The invention relates to stabilized compositions comprising fibroblast growth factor 2. The present invention also relates to dosage forms and methods of treating wounds, including tympanic membrane perforations, by administering the composition to a patient in need thereof.